Cargando…

ODP340 NOVEL THERAPY OSILODROSTAT AS AN OPTION FOR RECURRENT CUSHING'S DISEASE

INTRODUCTION: Cushing's Disease (CD) denotes a pathologic endogenous hypercortisolism secondary to excessive adrenocorticotropic hormone (ACTH) production. Cushing Disease is a rare condition with an estimated incidence of approximately 1.2-1.4 new cases / 1. 000. 000 per year. Although surgica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marin, Luis Madera, Nieves, Yadiel Rivera, Rivera, Monica Ortiz, Burgos, Alexandra Rosado, Cordero, Nicole Hernandez, Ortega, Nydia Burgos, Vick, Margarita Ramirez, Rodriguez, Loida Gonzalez, Alvarado, Milliete
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Neuroendocrinology and Pituitary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625218/ http://dx.doi.org/10.1210/jendso/bvac150.1049

Ejemplares similares

ODP342 Panhypopituitarism Induced by CTLA-4 and PD-1/PD-L1 Inhibitor Immunotherapy
por: Hernandez-Cordero, Nicole, et al.
Publicado: (2022)

ODP115 Primary Hyperparathyroidism in Pregnancy
por: Rosado-Burgos, Alexandra, et al.
Publicado: (2022)

ODP244 SGLT2 Inhibitor-Induced Euglycemic DKA and its Challenges
por: Penna, Laurianne El Musa, et al.
Publicado: (2022)

ODP550 Giant Cell Tumor of Bone: A Diagnostic Consideration of Sellar Lesions
por: Musa-Penna, Laurianne E, et al.
Publicado: (2022)

Hypothalamic Dysregulation; A Hidden Culprit in Multiple Sclerosis Symptoms
por: Hernandez-Cordero, Nicole Z, et al.
Publicado: (2021)

Pituitary Apoplexy in the Setting of Oral Anticoagulation Therapy With Apixaban
por: Rivera-Nieves, Yadiel, et al.
Publicado: (2021)

THU100 Case Of A Large Suprasellar-clival Mass: Prolactinoma Vs Paraganglioma
por: Madera Marin, Luis Norberto, et al.
Publicado: (2023)

ODP025 Adrenocortical Carcinoma: A Rare but Life-Threatening Malignancy
por: Ortiz-Rivera, Monica, et al.
Publicado: (2022)

THU038 Osilodrostat Dosing In Cushing’s Disease: A Pooled Analysis Of The LINC Program
por: Newell-Price, John, et al.
Publicado: (2023)

FRI329 COVID-19: An Uncommon Cause Of Hypophysitis
por: Medina-Torres, Wilnelia, et al.
Publicado: (2023)

SUN-454 Rationale and Methods for a Phase II Trial Evaluating Osilodrostat in Pediatric Patients with Cushing's Disease
por: Savage, Martin, et al.
Publicado: (2019)

Long-Term Control of Urinary Free Cortisol With Osilodrostat in Patients With Cushing’s Disease: Final Results From the LINC 2 Study
por: Fleseriu, Maria, et al.
Publicado: (2021)

ODP369 Weight Trajectory as a Predictor of Cushing's Disease
por: Thavaraputta, Subhanudh, et al.
Publicado: (2022)

ODP304 Cyclic Cushing Disease: A Diagnostic Challenge
por: Zubiran, Rafael, et al.
Publicado: (2022)

LBMON177 Dosing And Titration Of Osilodrostat In A Real-world Cohort Of US Patients With Endogenous Cushing's Disease: Analysis Of The ILLUSTRATE Study
por: Ioachimescu, Adriana Gabriela, et al.
Publicado: (2022)

LBMON176 Management, Safety, And Efficacy Of Osilodrostat Treatment In US Patients With Non-pituitary Cushing's Syndrome: Results From The ILLUSTRATE Study
por: Auchus, Richard Joseph, et al.
Publicado: (2022)

MON-257 Axenfeld Rieger Syndrome: An Uncommon Cause of Growth Hormone Deficiency
por: Santini, Alberto Javier Grana, et al.
Publicado: (2020)

ODP309 Ectopic Cushing's Syndrome: Importance of Methodical Approach to Hide and Seek
por: de Souza, Tamara G, et al.
Publicado: (2022)

OR16-2 Osilodrostat Treatment in Cushing's Disease (CD): Results from a Phase III, Multicenter, Double-Blind, Randomized Withdrawal Study (LINC 3)
por: Biller, Beverly MK, et al.
Publicado: (2019)

PMON163 Effect of Osilodrostat on Androgens and Adrenal Hormones in Patients With Cushing's Disease: Long-Term Findings From the Phase III, Prospective LINC 3 Study
por: Fleseriu, Maria, et al.
Publicado: (2022)

PMON160 Improvements in Clinical Signs of Hypercortisolism and Quality of Life According to Urinary and Late-Night Salivary Cortisol Levels in Patients with Cushing's Disease Treated with Osilodrostat
por: Biller, Beverly M K, et al.
Publicado: (2022)

ODP302 Cushing's Disease: A Challenging Diagnosis in Patients with Underlying Co-Morbidities
por: Campbell, Spencer, et al.
Publicado: (2022)

THU032 Osilodrostat Is Effective And Well Tolerated In Patients Of Asian And Non-Asian Origin With Cushing's Disease: A Pooled Analysis From LINC 3 And LINC 4
por: Snyder, Peter J, et al.
Publicado: (2023)

PMON162 Osilodrostat Provides Sustained Clinical Benefits and Improves Health-Related Quality of Life in Patients with Cushing's Disease: Results from the Phase III LINC 4 Study
por: Feelders, Richard, et al.
Publicado: (2022)

ODP303 Cushing's Syndrome Due to Ectopic Adrenocorticotropic Hormone-Secreting Metastatic Neuroendocrine Tumor
por: Cipriani, Allison, et al.
Publicado: (2022)

ODP603 Impact of CME at Improving Knowledge, Competence and Confidence Related to Management of Cushing Disease
por: Larkin, Amy, et al.
Publicado: (2022)

Osilodrostat Is an Effective and Well-Tolerated Treatment for Cushing’s Disease (CD): Results From a Phase III Study With an Upfront, Randomized, Double-Blind, Placebo-Controlled Phase (LINC 4)
por: Gadelha, Mônica, et al.
Publicado: (2021)

THU041 Clinical Improvements In Patients With Cushing’s Disease Treated With Osilodrostat According To Urinary And Late-night Salivary Cortisol Levels: Pooled Analysis From LINC 3 And LINC 4
por: Biller, Beverly M K, et al.
Publicado: (2023)

ODP624 A case of Cushing disease demonstrated rapid deterioration of clinical findings and marked hypercortisolemia
por: Hashimoto, Makiko, et al.
Publicado: (2022)

THU019 Osilodrostat As An Emergency Alternative For Hypercortisolism In A Patient With An Impaired Liver Function
por: Minasyan, Mari, et al.
Publicado: (2023)

OR27-3 Long-Term Results from the Phase III LINC 4 Study: Osilodrostat Maintained Normal Mean Urinary Free Cortisol in Patients with Cushing's Disease, with a Favorable Safety Profile
por: Auchus, Richard J, et al.
Publicado: (2022)

ODP322 Impact of Mifepristone on Liver Function and Resolution of Liver Steatosis in Patients with Cushing Syndrome – A Case Study
por: East, Honey E, et al.
Publicado: (2022)

ODP356 The Cortisol Conundrum: The Diagnostic Work up for Patients With Suspected Cushing's Disease and Hypercortisolaemia in Australia. Results of a Survey and Clinical Audit
por: Arulanantham, Jonathan, et al.
Publicado: (2022)

ODP349 Risk of Coronavirus Disease 2019 (COVID-19) in patients with Cushing's Disease (CD) is increased and independently associated with both obesity and disease activity
por: Mascarenhas Nakano, Bruna M, et al.
Publicado: (2022)

FRI340 Growth Hormone Deficiency Post Carbon Monoxide Poisoning
por: Ghamlouche, Ahmad Yehia, et al.
Publicado: (2023)

ODP339 Nonfunctioning Giant Adenomas
por: Oliveira, Miriam C, et al.
Publicado: (2022)

SAT-443 Osilodrostat Has No Clinically Relevant Effect on the Pharmacokinetic (PK) Profile of a Monophasic Oral Contraceptive in Healthy Females Receiving Cortisol Replacement Therapy
por: Breitschaft, Astrid, et al.
Publicado: (2019)

ODP314 Gynecomastia as the Initial Presentation of Acromegaly.
por: Lim, Frederick, et al.
Publicado: (2022)

ODP296 An unusual presentation of Glucagonoma syndrome.
por: Zare, Ahmad, et al.
Publicado: (2022)

ODP306 Diplopia as Presenting Manifestation of Acromegaly
por: Rjoob, Hani, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r9kqltdplo17q74mh7m1s0ns4i